Upadacitinib Treatment for Concurrent Atopic Dermatitis Vitiligo and Alopecia Areata
One drug improved skin, hair, and pigment in one man
A 57-year-old man with severe, refractory skin conditions showed significant improvement in dermatitis, vitiligo, and hair loss on upadaciti…
A single patient with three skin conditions saw dramatic improvement after taking upadacitinib for one year.
Systematic review and meta-analysis on alopecia areata and skin cancer risk
Alopecia areata patients may have lower risk of certain skin cancers based on new review data
This systematic review and meta-analysis synthesized eight studies on skin cancer risk in patients with alopecia areata. The analysis found …
This review found that people with hair loss might have a lower chance of getting melanoma. Other skin cancers showed a similar trend but th…
Pilot Study Shows 2% Salicylic Acid Shampoo Reduces Scab Severity in Androgenetic Alopecia Patients
Simple wash removes scabs after hair transplant surgery
This prospective, multicenter, single-arm pilot study evaluated 21 male patients using a 2% salicylic acid shampoo.
A new shampoo formula helps clear scabs after hair transplant surgery without causing pain or irritation for most patients.
Autoimmune Thyroiditis Prevalence Higher in Obese Women With PCOS in Retrospective Cohort Analysis
New PCOS Data Reveals Hidden Thyroid Risks
This retrospective cohort study evaluated 1,249 women with PCOS aged 18–44 years.
Women with PCOS should check their thyroid health regularly.
Baricitinib maintains SALT score ≤20 in adults with severe alopecia areata over 152 weeks
Baricitinib maintained hair regrowth in severe alopecia areata for over three years in this trial
This phase 3 RCT evaluated continuous baricitinib in 196 adults with severe alopecia areata.
Baricitinib kept hair growing on the scalp, eyebrows, and eyelashes for over three years in adults with severe alopecia areata who responded…
Deuruxolitinib 8 or 12 mg BID improved SALT20 response versus placebo in severe alopecia areata
Hair Regrowth Drug Shows Strong Results in Major Trial
This Phase 3 randomized, double-blind, placebo-controlled, multicenter trial enrolled 517 adults aged 18 to 65 years with severe chronic alo…
A new drug helped 38% of adults with severe hair loss regrow most of their hair in just six months during a major trial.
Phase 2 trial finds topical STS01 1% improves SALT scores in patchy alopecia areata
A New Topical Treatment Shows Promise for Patchy Hair Loss
A phase 2 randomized controlled trial in 155 adults with mild to moderate patchy alopecia areata found that daily topical STS01 1% for 6 mon…
A new, easy-to-apply cream could offer a much-needed treatment option for a common and distressing form of autoimmune hair loss.
Centralized hair loss measurement showed better agreement and 50% lower error margins than local rating in mild-to-moderate Alopecia Areata
Centralized hair loss scoring showed better consistency than local ratings in mild Alopecia Areata trials
This Phase 2 clinical trial compared centralized measurement of hair loss via standardized photographic images against local SALT score rati…
Centralized hair loss scoring cut measurement errors by half compared to local ratings in mild Alopecia Areata trials, boosting trial succes…
Phase 2 trial: Topical STS01 shows dose-related hair regrowth in mild-moderate alopecia areata
Topical treatment shows hair regrowth in alopecia areata, but quality of life unchanged
A Phase 2 randomized controlled trial in patients with mild to moderate patchy alopecia areata found that topical STS01 (dithranol) produced…
A new topical treatment regrows hair in patchy alopecia, yet patients report no improvement in daily life or feelings even with full regrowt…
Phase 3 trial of low-dose IL-2 versus placebo for severe alopecia areata completed in 44 patients
Phase 3 trial tests low-dose IL-2 for severe alopecia areata, results pending
A Phase 3, prospective, randomized, double-blind, multicenter trial compared low-dose IL-2 to placebo in 44 patients with severe alopecia ar…
A major late-stage trial testing low-dose IL-2 for severe alopecia areata has finished, but results on hair regrowth are not yet available.